Politics
Eli Lilly (LLY) has filed six lawsuits against medical spas, a compounding pharmacy and other vendors over alleged counterfeit retatrutide sales, Axios reports
StockNow breaking-news AI analysis
Eli Lilly filed six lawsuits and reported over 200 entities to regulators to combat illicit sales and advertising of its unapproved obesity drug retatrutide.
News detail
The company is also referring thousands of sellers to regulators and law enforcement and urging payment processors and social-media platforms to restrict advertising and payments for the unapproved weight-loss drug
Related stocks
1 stocks
What do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.